
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.
The deal represents an implied value of $13 per Astria share, and approximately $700 million in enterprise value.